Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2013

View Archived Issues

GlaxoSmithKline presents new agents for HCV infection

CLIC3 identified as a marker of breast cancer prognosis

Scientists discover a new chimeric gene associated with myeloma

First-in-human study data reported for ACE-536

Novel phosphodiesterase inhibitors patented by Nycomed (Takeda Pharmaceutical)

Basilea Pharmaceutica discloses new antibacterial agents

Boehringer Ingelheim Pharma patents new CCR2 receptor antagonists

IntraCellular Therapies prepares novel PDE1A inhibitors

Aurigene Discovery Technologies divulges novel hPD-1 inhibitors

BrainStorm's NurOwn trial is fast-tracked to phase IIa

First-in-human phase I study begins for TGR-1202

The methodology and application of a single-cell, genome-wide analysis of genetic polymorphisms

Phase I RenaZorb data support further development

Advanced Cell Technology gives update on phase I/II stem cell trials in SMD and AMD

Takara Bio begins phase I trial of HIV-1 gene therapy

Baxter reports phase III data for FEIBA NF

FDA approves Kineret for the treatment of NOMID

Tobira Therapeutics reports data from phase IIb cenicriviroc trial

Uluru begins launch of Altrazeal in Europe

Chugai and Debiopharm enter license agreement for anticancer agent

FDA and EMA to review GE Healthcare's applications for flutemetamol (18F)

Novel allergic dermatitis model in pigs reveals activity of escin

GSK and Theravance submit MAA for umeclidinium bromide/vilanterol

Bayer's Skyla approved by FDA to prevent pregnancy for up to 3 years

Takeda launches Lotriga 2 g for the treatment of hyperlipidemia in Japan

Biocon receives marketing authorization in India for itolizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...